Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 4/20 | 0.56 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.56 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | TSHR | P16473 | 1/20 | 0.48 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.48 |
| ▸ | HBB | P68871 | 1/20 | 0.48 |
| ▸ | TK1 | P04183 | 5/20 | 0.46 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.40 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.40 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.40 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.39 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10515432 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL10171969 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL10514666 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL10515491 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL600100 | 1.00 | LMNA (0.56) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL29325519 | 0.96 | LMNA (0.55) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL22902101 | 0.96 | LMNA (0.55) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL29323413 | 0.96 | LMNA (0.55) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL29325522 | 0.96 | LMNA (0.55) | LMNASMN1; SMN2MAPTTSHRPMP22 | |
| SCHEMBL9311378 | 0.92 | LMNA (0.62) | LMNASMN1; SMN2MAPTTSHRPMP22 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8114994-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2012-02-14 | — | — | US | disclosed |
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2009-06-11 | — | — | US | disclosed |
| US-7495006-B2 | 2′ and 3′-substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY (US) | 2009-02-24 | — | — | US | disclosed |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | EMORY UNIVERSITY | 2006-10-05 | — | — | US | disclosed |
| EP-0330992-A2 | Novel cyclobutane Derivatives, processes for their preparation and pharmaceutical compositions comprising them | Nippon Kayaku Kabushiki Kaisha (JP) | 1989-09-06 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090149416-A1 | 2' and 3'-Substituted Cyclobutyl Nucleoside Analogs for the Treatment Viral Infections and Abnormal Cellular Proliferation | HAVCR2, PNP, PCNA | LMNA 2156/4885SMN1; SMN2 1275/4885MAPT 2646/4885 |
| US-20060223835-A1 | 2' and 3'- substituted cyclobutyl nucleoside analogs for the treatment of viral infections and abnormal cellular proliferation | HAVCR2, PNP, DCTD | LMNA 2607/4885SMN1; SMN2 1385/4885MAPT 2376/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.